Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR 2,274.25
-108.40 (-4.55%)
At close: May 29, 2026
Glenmark Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 167,114 | 133,217 | 118,131 | 115,832 | 123,049 |
Other Revenue | 7,317 | 415.54 | 8,323 | 723.29 | - |
| 174,431 | 133,633 | 126,454 | 116,556 | 123,049 | |
Revenue Growth (YoY) | 30.53% | 5.68% | 8.49% | -5.28% | 12.44% |
Cost of Revenue | 47,475 | 45,250 | 45,789 | 44,108 | 45,481 |
Gross Profit | 126,957 | 88,383 | 80,665 | 72,448 | 77,568 |
Selling, General & Admin | 35,779 | 36,814 | 34,465 | 31,833 | 29,176 |
Other Operating Expenses | 40,848 | 27,639 | 25,924 | 23,541 | 25,124 |
Operating Expenses | 82,361 | 69,314 | 66,208 | 61,066 | 59,168 |
Operating Income | 44,596 | 19,069 | 14,457 | 11,382 | 18,400 |
Interest Expense | -2,087 | -2,071 | -5,160 | -3,490 | -2,981 |
Interest & Investment Income | - | 439.41 | 61.78 | 73.52 | 97.85 |
Currency Exchange Gain (Loss) | - | 282.27 | - | 2,035 | 880.54 |
Other Non Operating Income (Expenses) | - | - | - | - | 688.35 |
EBT Excluding Unusual Items | 42,508 | 17,720 | 9,359 | 10,000 | 17,086 |
Gain (Loss) on Sale of Assets | - | - | 15.3 | 57.25 | -64.64 |
Legal Settlements | - | - | - | -8,011 | - |
Other Unusual Items | -22,661 | -3,728 | -9,010 | 351.99 | -2,609 |
Pretax Income | 19,847 | 13,992 | 364.95 | 2,398 | 14,412 |
Income Tax Expense | 6,228 | 3,521 | 18,673 | 3,294 | 4,476 |
Earnings From Continuing Operations | 13,620 | 10,471 | -18,309 | -895.61 | 9,936 |
Earnings From Discontinued Operations | - | - | 3,973 | 4,670 | - |
Net Income to Company | 13,620 | 10,471 | -14,335 | 3,774 | 9,936 |
Minority Interest in Earnings | -1.01 | -0.45 | -681.46 | -801.55 | -519.38 |
Net Income | 13,619 | 10,471 | -15,017 | 2,972 | 9,417 |
Net Income to Common | 13,619 | 10,471 | -15,017 | 2,972 | 9,417 |
Net Income Growth | 30.06% | - | - | -68.44% | -2.92% |
Shares Outstanding (Basic) | 282 | 282 | 282 | 282 | 282 |
Shares Outstanding (Diluted) | 282 | 282 | 282 | 282 | 282 |
Shares Change (YoY) | 0.03% | 0.01% | 0.00% | - | - |
EPS (Basic) | 48.26 | 37.11 | -53.22 | 10.53 | 33.37 |
EPS (Diluted) | 48.24 | 37.11 | -53.22 | 10.53 | 33.37 |
EPS Growth | 30.00% | - | - | -68.43% | -2.93% |
Free Cash Flow | 20,873 | -15,772 | -11,638 | 176.29 | 3,185 |
Free Cash Flow Per Share | 73.94 | -55.89 | -41.24 | 0.63 | 11.29 |
Dividend Per Share | - | 2.500 | 2.500 | 2.500 | 2.500 |
Gross Margin | 72.78% | 66.14% | 63.79% | 62.16% | 63.04% |
Operating Margin | 25.57% | 14.27% | 11.43% | 9.77% | 14.95% |
Profit Margin | 7.81% | 7.84% | -11.88% | 2.55% | 7.65% |
Free Cash Flow Margin | 11.97% | -11.80% | -9.20% | 0.15% | 2.59% |
EBITDA | 50,330 | 21,676 | 18,297 | 14,289 | 19,124 |
EBITDA Margin | 28.85% | 16.22% | 14.47% | 12.26% | 15.54% |
D&A For EBITDA | 5,735 | 2,607 | 3,840 | 2,907 | 723.93 |
EBIT | 44,596 | 19,069 | 14,457 | 11,382 | 18,400 |
EBIT Margin | 25.57% | 14.27% | 11.43% | 9.77% | 14.95% |
Effective Tax Rate | 31.38% | 25.16% | 5116.72% | 137.34% | 31.06% |
Revenue as Reported | 174,431 | 134,355 | 126,531 | 118,721 | 124,716 |
Advertising Expenses | - | 6,079 | 5,157 | 5,270 | 4,349 |